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Key Summary Points
Aim To provide a geriatric perspective on the 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation 
developed in collaboration with the European Association of Cardio–Thoracic Surgery (EACTS).
Findings While the large majority of AF patients in real life are older, frail and cognitively impaired, these are mostly 
excluded from clinical trials, and physicians’ attitudes often prevail over standardized algorithms. On the basis of existing 
evidence, we suggest that (1) opportunistic AF screening by pulse palpation or ECG rhythm strip is cost-effective, and (2) 
whereas advanced chronological age by itself is not a contraindication to AF treatment, a Comprehesive Geriatric Assess-
ment (CGA) including frailty, cognitive impairment, falls and bleeding risk may assist in clinical decision making to provide 
the best individualized treatment.
Message The integration of CGA might positively influence clinical decision making in older patients with atrial fibrillation.
Abstract
Background The Task Force for the diagnosis and management of atrial fibrillation (AF) of the European Society of Car-
diology (ESC) published in 2020 the updated Guidelines for the Diagnosis and Management of Atrial Fibrillation with the 
contribution of the European Heart Rhythm Association (EHRA) of the ESC and the European Association for Cardiotho-
racic Surgery (EACTS).
Methods and results In this narrative viewpoint, we approach AF from the perspective of aging medicine and try to provide 
the readers with information usually neglected in clinical routine, mainly due to the fact that while the large majority of AF 
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patients in real life are older, frail and cognitively impaired, these are mostly excluded from clinical trials, and physicians’ 
attitudes often prevail over standardized algorithms.
Conclusions On the basis of existing evidence, (1) opportunistic AF screening by pulse palpation or ECG rhythm strip is 
cost-effective, and (2) whereas advanced chronological age by itself is not a contraindication to AF treatment, a Compre-
hensive Geriatric Assessment (CGA) including frailty, cognitive impairment, falls and bleeding risk may assist in clinical 
decision making to provide the best individualized treatment.
Keywords Atrial fibrillation · Advanced age · Older patients · Anticoagulation · Cognitive impairment
Introduction
The Task Force for the diagnosis and management of atrial 
fibrillation (AF) of the European Society of Cardiology 
(ESC) published in 2020 the updated Guidelines for the 
Diagnosis and Management of Atrial Fibrillation with the 
contribution of the European Heart Rhythm Association 
(EHRA) of the ESC and the European Association for Car-
diothoracic Surgery (EACTS) [1]. As the authors state in the 
preamble “(…) The complexity of AF requires a multifac-
eted, holistic and multidisciplinary approach to the manage-
ment of AF… with the goal to further improve the structured 
management of AF patients, promote patient values, and 
finally improve patient outcomes… the Task Force includes 
cardiologists with varying subspecialty expertise, cardiac 
surgeons, methodologists and specialist nurses amongst its 
members (…).”. Reflecting the composition of the panel, 
this holistic “ABC strategy (A: anticoagulation/avoid stroke, 
B: better symptom control, C: detection and management 
of cardiovascular risk factors and concomitant diseases)” 
includes several developments with respect to the 2016 ESC 
guidelines [2], mainly focused on drug therapies (Table 1).
While the critical role of the ESC guidelines for the man-
agement of AF is out of the question, from a geriatric per-
spective such “holistic approach” comes short to address 
the complexity of older AF patients. Due to the nature of 
the aging process, in fact, there are crucial characteristics 
of older patients that, if neglected, often undermine, some-
times nullify the most perfect organ-centered treatment plan. 
These include multifactoriality, heterogeneity, atypical dis-
ease presentation, geriatric cascade, frailty just to mention 
a few. The appropriate use of the tools of geriatric medi-
cine allows to balance the net clinical benefit of screening 
and therapeutic decisions and might be most appropriately 
shared and used in a meaningful interdisciplinary comanage-
ment. On behalf of the Special Interest Group "Cardiovas-
cular Diseases" of the European Geriatric Medicine Society 
(EuGMS), the aim of this overview is the disentanglement 
of age-related complexity by discussing specific questions 
arising in advanced age such as screening for AF, interplay 
with frailty, cognitive impairment, functional loss and falls. 
Furthermore, physicians’ attitudes and uncertainties in pre-
scribing oral anticoagulant therapy (OAT) will be addressed.
Atrial fibrillation in advanced age
Age is an independent risk factor for the development of AF 
[3, 4]. In 2010, the number of older individuals (≥ 75 years 
old) with AF in the European Union was estimated to be 
5.6 million, but this is expected to double to 13.8 million by 
2060, when subjects aged 80+ years will represent 65.2% of 
total AF cases in European Union [1, 5]. The relationship 
of AF with increased risk of thromboembolism, stroke and 
mortality is well-established [3]. Patients with AF exhibit 
increased hospitalizations due to stroke, heart failure, need 
for pacemaker implantation and adverse effects related to 
anticoagulant and antiarrhythmic therapy. In addition, there 
are other known specific, but often overlooked problems 
closely related to AF in this population, including cognitive 
impairment with and without dementia, frailty, decline in 
physical performance and loss of independence [6–8].
“Older people” include a very heterogeneous group of 
individuals, varying from independent and robust persons to 
dependent and very frail ones [9]. Age-related physiologic 
changes (low body mass index, altered body composition 
of muscle and fatty tissue), multimorbidity and polyphar-
macy (with high frequency of renal impairment, altered 
pharmacokinetic profile of drugs and high risk of drug–drug 
interactions), frailty, cognitive impairment and functional 
limitations and life-expectancy are factors that should be 
taken into account in clinical decision making [9]. In such 
a complex population, not suitable to general recommenda-
tions, the correct clinical approach is essential to offer the 
best medical care and, at the same time, to avoid harm and 
futility [8–10]. Although guidance exists for inclusion of 
older patients in clinical trials [11], these are still under-
represented in randomized clinical trials (RCTs), whereas 
the most robust, independent and cognitively intact older 
patients fit are usually enrolled [12]. Although the Compre-
hensive Geriatric Assessment (CGA) and frailty measure-
ment tools have been recommended to help guide decisions 
about AF anticoagulation in older patients [13, 14], this is 
not generalized in clinical trials nor current practice yet.
As a matter of fact, older patients represent the largest 
majority of those with AF [1]. Notwithstanding, most rec-
ommendations, including the recent 2020 ESC guidelines 
for AF management, stem from RCTs poorly representative 
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of real-world older people, and come short to deal with the 
complex health characteristics of these patients [15].
Challenges of atrial fibrillation in real life
Screening
In addition to increasing prevalence of clinical AF with 
advancing age, a significant number of older individu-
als do not show any symptoms despite going through an 
episode of AF [16]. Unfortunately, asymptomatic (silent) 
AF is independently associated with stroke and mortality 
to a similar extent compared to symptomatic AF [17]. It 
is estimated that 1.3% of the population aged ≥ 65 have 
undiagnosed, largely asymptomatic AF [18]. Patients with 
incidentally detected AF treated with OAT have stroke 
rates similar to matched individuals without AF [19]. Fur-
thermore, their adjusted stroke and death rates are reduced, 
compared with those who are not treated or are treated 
with aspirin alone [19]. This provides justification for 
AF screening in high-risk populations. Of note, the 2020 
ESC Guideline for AF management strongly recommends 
opportunistic screening of AF by pulse taking or ECG 
rhythm strip in patients ≥ 65 years of age [1].
Table 1  Changes in the ESC 
recommendations on atrial 
fibrillation, 2016–2020 [1, 2]. 
Mod. from [2]
Changes in the recommendaons
ssalC0202 a ssalC6102 a
Recommendaons about integrated AF management
To opmize shared decision making 
about specific AF treatment opon(s) 
in consideraon it I recommended 
that: 
• Physicians inform the paent about 
advantages /limitaons and 
benefit/risks associated with 
considered treatment opon(s); and 
• Discuss the potenal burden of the 
treatment with the paent and include 
the paent’s percepon of treatment 
burden in the treatment decision. 
I Placing paents in a central role in 
decision making should be considered 
in order to tailor management to 
paent preferences and improve 
adherence to long-term therapy 
IIa 
Recommendaons for the prevenon of thrombo-embolic events in AF
For bleeding risk assessment, a formal 
structured risk-score-based bleeding 
risk assessment is recommended to 
help idenfy non-modifiable and 
address modifiable bleeding risk 
factors in all AF paents, and to 
idenfy paents potenally at high risk 
of bleeding who should be scheduled 
for early and more frequent clinical 
review and follow-up. 
I Bleeding risk scores should be 
considered in AF paents on oral 
ancoagulaon to idenfy modifiable 
risk factors for major bleeding. 
IIa 
In paents on VKAs with low me in 
INR therapeuc range (eg. TTR<70%), 
recommended opons are: 
• Switching to NOAC but ensuring 
good adherence and persistence with 
therapy; or  
I AF paents already on treatment with 
a VKAs may be considered for NOAC 
treatment if TTR is not well controlled 
despite good adherence, or if paent 
preference without contraindicaons 
to NOAC (eg. Prosthec valve). 
IIb 
• Efforts to improve TTR (eg. 
Educaon/conselling and more 
frequent INR checks). 
IIa
Recommendaons for rhythm control/catheter ablaon of AF
AF catheter ablaon aer drug therapy failure
AF catheter ablaon for PVI is 
recommended for rhythm control 
aer one failed or intolerant class I or 
III AAD, to improve symptoms of AF 
recurrences in paents with:  
• Paroxysmal AF, or  
• Persistent AF without major risk 
factors for AF recurrence, or  
• Persistent AF with major risk factors 
for AF recurrence. 
I Catheter or surgical ablaon should be 
considered in paents with 
symptomac persistent or long-
standing persistent AF refractory to 
AAD therapy to improve symptoms, 
considering paent choice, benefit and 
risk, supported by an AF Heart Team. 
IIa 
First-line therapy 
AF catheter ablaon:  
• Is recommended to reverse LV 
dysfuncon in AF paents when 
tachycardia-induced cardiomyopathy 
is highly probable, independent of 
their symptom status. 
I AF ablaon should be considered in 
symptomac paents with AF and 
HFrEF to improve symptoms and 
cardiac funcon when 
tachycardiomyopathy is suspected. 
IIa 
• Should be considered in selected AF 
paents with HFrEF to improve 
survival and reduce HF hospitalizaon. 
IIa
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Table 1  (continued) Techniques and technologies 
Complete electrical isolaon of the 
pulmonary veins is recommended 
during all AF catheter-ablaon 
procedures. 
I Catheter ablaon should target 
isolaon of the pulmonary veins using 
radiofrequency ablaon or cryothermy 
balloon catheters. 
IIa 
If paent has a history of CTI-
dependent atrial fluer or if typical 
atrial fluer is induced at the me of 
AF ablaon, delivery of a CTI lesion 
may be considered. 
IIb Ablaon of common atrial fluer 
should be considered to prevent 
recurrent fluer as part of an AF 
ablaon procedure if documented or 
occurring during the AF ablaon. 
IIa 
Lifestyle modificaon and other strategies to improve outcomes of ablaon
Weight loss is recommended in obese 
paents with AF, parcularly those 
who are being evaluated to undergo 
AF ablaon. 
I In obese paents with AF, weight loss 
together with management of other 
risk factors should be considered to 
reduce AF burden and symptoms. 
IIa 
Recommendaons for stroke risk management peri-cardioversion
In paents with AF undergoing 
cardioversion, NOACs are 
recommended with at least similar 
efficacy and safety as warfarin. 
I An
coagula
on with heparin or a 
NOAC should be ini
ated as soon as 
possible before every cardioversion of 
AF or atrial fluer. 
IIa 
Recommendaons for stroke risk management peri-catheter ablaon
Aer AF catheter abla
on, it is 




warfarin or a NOAC is con
nued for at 
least 2 months post abla
on, and  
• Long-term con
nua
on of systemic 
an
coagula
on beyond 2 months post 
abla
on is based on the pa
ent’s 
stroke risk profile and not on the 




ents should receive oral 
an
coagula




Recommendaons for long-term anarrhythmic drugs
Amiodarone is recommended for long-
term rhythm control in all AF pa
ents, 
including those with HFrEF. However, 
owing to its extracardiac toxicity, other 
AADs should be considered first 
whenever possible. 
I Amiodarone is more effec
ve in 
preven
ng AF recurrences than other 
AAD, but extracardiac toxic effects are 
common and increase with 
me. For 
this reason, other AAD should be 
considered first. 
IIa 
Recommendaons for lifestyle intervenons and management of risk factors and concomitant 
diseases in paents with AF 
Aenon to good BP control is 
recommended in AF paents with 
hypertension to reduce AF recurrences 
and risk of stroke and bleeding. 
I BP control in ancoagulated paents 
with hypertension should be 
considered to reduce the risk of 
bleeding 
IIa 
Physical acvity should be considered 
to help prevent AF incidence or 
recurrence, with the excepon of 
excessive endurance exercise, which 
may promote AF. 
IIa Moderate regular physical acvity is 
recommended to prevent AF, while 
athletes should be counselled that 
long-lasng intense sports 
parcipaon can promote AF 
I 
Opmal management of OSA may be 
considered, to reduce AF incidence, AF 
progression, AF recurrences, and 
symptoms. 
IIb OSA treatment should be opmized to 
reduce AF recurrences and improve AF 
treatment results. 
IIa 
Recommendaons for stroke prevenon in AF paents aer ICH
n AF paents at high risk of ischaemic 
stroke, (re-)iniaon of OAC, with 
preference for NOACs over VKAs in 
NOAC-eligible paents, should be 
considered in consultaon with a 
neurologist/ stroke specialist aer:  
• A trauma-related ICH  
• Acute spontaneous ICH (which 
includes subdural, subarachnoid, or 
intracerebral haemorrhage), aer 
careful consideraon of risks and 
benefits 
IIa Aer ICH oral ancoagulaon in 
paents with AF may be reiniated 
aer 48 weeks provided the cause of 
bleeding or the relevant risk factor has 
been treated or controlled. 
IIb 
Recommendations for postoperative AF 
Long-term OAC therapy to prevent 
thrombo-embolic events may be 
considered in paents at risk for stroke 
with postoperave AF aer cardiac 
surgery, considering the ancipated 
net clinical benefit of OAC therapy and 
informed paent preferences. 
IIb Long-term ancoagulaon should be 
considered in paents with AF aer 
cardiac surgery at risk for stroke, 
considering individual stroke and 
bleeding risk. 
IIa 
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A screening program is accepted as efficient if it shows 
high sensitivity and can be carried out with low costs and 
risks. There are several screening tools in use for AF detec-
tion which are quite comparable in terms of their sensitivity, 
specificity and ease of application. Pulse palpation is a tradi-
tional and proven to be effective method for AF screening in 
older adults [20]. Oscillometric blood pressure monitors and 
smartphone applications reported to have higher sensitivity 
and specificity values, although the validation studies are 
conducted in small number of participants [21, 22]. There 
are also single-lead handheld devices that provide an ECG 
strip, which offers an advantage of confirmation of diagnosis 
with an ECG recording. These devices also reported to be 
very effective and have been widely used in AF screening 
studies [23, 24]. Wearable continuous ECG monitors have 
been demonstrated to be well tolerated and to increase AF 
detection tenfold, compared with oscillometric screening 
with a BP monitor [25].
All of these screening methods seem advantageous in 
older adults in terms of being practical, as patients remain 
seated, pass through brief measurements and do not need to 
undress. However, they also bring some disadvantages. Pulse 
palpation is the tool of choice for opportunistic screening 
due to its high sensitivity and cost effectiveness. Unfortu-
nately, pulse is infrequently assessed in routine care. Cardiac 
auscultation can be the other option for detecting irregular 
heartbeats, but it is also less frequently preferred. There 
are several applications in use, however, most of them are 
not clinically validated. In addition, some of them require 
a noise-free trace for optimal performance. Furthermore, 
although they provide high sensitivity, their specificity is 
lower which can cause anxiety, create extra work and cost 
verifying diagnosis with an ECG [26]. Although the inter-
est of the older population in technology has increased in 
recent years, the rate of use of smart phones or other devices 
with advancing age has not been proven yet. This makes the 
self-initiating, telemedical or wearable-based screening of 
AF currently not realistic, especially in oldest-old, cogni-
tively impaired and very frail individuals. Hence, the opti-
mum choice of AF screening tool is still a debate and mostly 
depends on patient profile and screening setting.
Another controversy regarding AF screening in older 
adults is which strategy of screening is more effective. 
According to a recent meta-analysis, there was no statisti-
cally significant difference between opportunistic (offered as 
part of a routine medical evaluation) and systematic (gen-
eral or targeted screening of a high-risk population) screen-
ing [27]; yet, opportunistic screening is likely to be more 
cost-effective [28]. Settings that have been used effectively 
include community-based and others based in primary care, 
specialist practices, general or specialist clinics or pharma-
cies [29]. Indeed, primary care physicians have the potential 
to be at the forefront in screening programs. One of the big-
gest challenges about the settings is ensuring the link for 
referral to confirm diagnosis and establish proper work-up. 
In terms of providing a direct link with diagnosis, treatment 
and follow-up, primary care and outpatient clinics seem the 
most advantageous. In fact, health resources vary widely 
between countries and health systems. Therefore, the setting 
and strategy for screening should be country and health-
system specific [29].
In this context, the best available evidence suggests that 
opportunistic screening of AF in older population is cost-
effective and should be performed. Older AF patients with-
out cognitive impairment can be educated for checking their 
pulses intermittently, as self-detection of AF through pulse 
palpation was shown feasible in older adults [30]. Annual 
events (like influenza vaccination) can be a good opportu-
nity for screening in this particular population [31, 32]. The 
introduction of health checks including AF screening in gen-
eral practice, and obligation of presenting practice reports 
(like the General Practice contract developed in 1990 in 
England) [33], may increase detection of AF. In addition 
to primary health care workers, staff working in secondary 
and tertiary health care units dealing with older adults, and 
also nursing home staff should be educated for importance 
of AF detection and ECG interpretation in a routine basis. 
In addition to opportunistic screening, systematic screening 
programs for patients aged ≥ 75 years should be considered, 
since a significant number of this age group are vulnerable to 
AF outcomes due to their comorbidities, frailty, and cogni-
tive impairments [1].
Patients’ global health status
Patients with AF in clinical practice are older, have higher 
disease burden and are more frequently affected by func-
tional limitations and dementia than those enrolled in RCTs 
[34]. Moreover, direct oral anticoagulants (DOACs) trials 
as well as observational studies did not consider geriatric 
AAD antiarrhythmic drug, AF atrial fibrillation, BP blood pressure, CTI cavotricuspid 
isthmus, HFrEF heart failure with reduced ejection fraction, ICH intracranial haem-
orrhage, INR international normalized ratio, LV left ventricular, LVEF left ventricular 
ejection fraction, NOAC non-vitamin K antagonist oral anticoagulant, OAC oral anti-
coagulant or oral anticoagulation, PVI pulmonary vein isolation, TTR time in thera-
peutic range, VKA vitamin K antagonist
a Class of recommendation
Table 1  (continued)
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syndromes such as frailty, cognitive impairment and func-
tional dependence, which have been demonstrated to influ-
ence physicians’ decision about DOACs use in older persons 
[34]. Therefore, beyond conventional embolic and bleeding 
risk scores, a decision-making guidance that incorporates 
factors such as frailty and dementia would be more help-
ful in determining the therapeutic approach. Indeed frailty, 
dementia and disability are among the most commonly cited 
reasons for OAT under-prescription, although evidence to 
support this decision is controversial [4].
Frailty
It has been reported that cardiologists subjectively identify 
frailty in the presence of problems in motility, cognition, 
malnutrition and sarcopenia [35]. In this context, frail and 
frailty are terms frequently used to label some older person 
on the basis of a subjective mix of disease burden, poor 
health status and cognitive or functional impairment. In the 
wide armamentarium of frailty tools, there are two basic 
conceptualizations of frailty. The Cardiovascular Health 
Study (CHS)-derived frailty “phenotype” identifies a sarco-
penia-dependent model of frailty, which is diagnosed when 
at least three of five criteria among slow gait speed, low 
physical activity, unintentional weight loss, self-reported 
exhaustion and muscle weakness are recognized. In the 
seminal paper by Fried et al. this frailty phenotype was 
demonstrated to be associated with several adverse clini-
cal outcomes, including worsening mobility and disability, 
hospitalizations and mortality over 7 years in community-
dwelling older persons [36]. In recent years, several other 
tools have been proposed to identify this frailty phenotype, 
including the Simplified Fried test [37], the Short Physical 
Performance Battery (SPPB) [38], the 5 m gait speed [39], 
the Study of Osteoporotic Fractures (SOF) index [40, 41], 
the simple Frail Scale [42] and the SARC-F questionnaire 
[43]. A quite different approach to frailty conceptualiza-
tion was developed by Rockwood et al. with the Canadian 
Study of Health and Aging (CSHA)-derived Frailty Index 
(FI) [44]. This is a 70-item form based on the accumulation 
of deficits (including functional limitations and disabilities, 
cognitive and sensory impairment, psychosocial variables 
and number of diseases), and its score is associated with 
increased probability of short-term risk of institutionaliza-
tion, mortality and hospitalization. These authors further 
developed the seven-point Clinical Frailty Scale (CFS, a 
semi-quantitative eye-ball global judgement of frailty or 
vulnerability), which proved to be correlated with the FI 
and associated with increased risk of mortality and institu-
tionalization [45]. The Multidimensional Prognostic Index 
(MPI) [46] (which is derived by a formal CGA through the 
inclusion of functional cognitive, nutritional and comor-
bidity scores and social support network) has also been 
demonstrated to be predictive of mortality and adverse clini-
cal outcomes [47, 48].
The ESC guidelines for the diagnosis and management 
of AF (section 11.13) [1] state that “frailty, comorbidities, 
and increased risk of falls do not outweigh the benefits 
of OAT”. However, despite we can concur with this sim-
ple statement, OAT prescription in older AF patients yet 
remains a troublesome decision, and persisting uncertainties 
are well represented by the current underuse of appropriate 
OAT in frail older patients with AF, despite their increased 
risk of embolic stroke and death [15, 34, 49]. Wilkinson 
et al recently suggested that “The lack of evidence to guide 
optimal care for patients with AF and frailty might in part 
explain the gap between current guidelines and clinical prac-
tice in management of these patients” [7].
Chronological age per se is not an acceptable criterion 
to guide clinical decision making, as convincingly demon-
strated during the SARS-Cov-2 pandemic [50]. As both the 
CGA and the MPI are time-demanding procedures in daily 
clinical practice, it is difficult to implement them systemati-
cally in cardiology or general internal wards. In the quest for 
an easier alternative to this complex assessment, “frailty” 
appeared as a captivating surrogate. However, the growing 
number of frailty tools available, and the limited consensus 
on how to define and measure this complex state have gen-
erated confusion in several clinical settings, including the 
persistent uncertainties around the clinical benefit of OAT 
in frail older patients. We argue that most of these uncer-
tainties might originate from the different clinical implica-
tions linked to the adoption of different frailty tools. Indeed, 
albeit under the same definition of “frailty”, the two basic 
different conceptualizations (frailty phenotype vs accumula-
tion of deficits) recognize different individuals and generate 
different clinical and prognostic implications. Whereas the 
CHS-frailty phenotype identifies patients at risk of adverse 
clinical outcomes in the presence of stressors [36], both the 
CFS and the FI recognize patients with global poor health 
status and with limited survival [36, 51–55]. Therefore, it is 
not surprising that using different tools to recognize “frailty” 
may identify older persons with rather different health status 
and residual life-span , thereby leading to discordant con-
clusions in many clinical settings, including AF [34, 56], 
and may generate confusion among expertise areas outside 
geriatrics.
Although a recent systematic review and meta-analysis 
on the management of AF for older persons with frailty 
concluded that “frailty is highly prevalent and associated 
with adverse clinical outcomes, and that there is a lack of 
evidence on the interaction of frailty and OAT with clini-
cal outcomes to guide optimal care in this setting” [7], on 
the basis of current evidence it seems reasonable that older 
persons with AF and the “frail phenotype” might be con-
sidered for OAT, because of an expected net clinical benefit 
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[34, 56–60], whereas at the moment there is scant, if any, 
evidence of benefit in those with severe frailty according to 
the FI/CFS, who are also more frequently denied OAT [7, 
61, 62].
Cognitive impairment and falls
Within the frame of the increasing exploitation of the con-
cept of multidimensional frailty [63], particular attention 
should be offered to the bidirectional effects of cognitive 
decline and AF. If, in fact, AF-related stroke predisposes to 
dementia, there is an association between AF and dementia 
independent of stroke which demands a great deal of atten-
tion when managing older patients. Usually, the focus of 
healthcare practitioners concentrates on new-onset dementia, 
as about one-third of all stroke patients develop the condi-
tion within 5 years and AF patients have a 2.7-fold demen-
tia risk after stroke [64, 65]. Two meta-analyses revealed ≈ 
30% increased risk of dementia in AF after adjustment for 
cerebrovascular events [65, 66]. Furthermore, AF is related 
to cognitive impairment or dementia in younger ages [67]. 
In these studies, no brain imaging was performed to rule 
out clinically silent strokes as the underlying pathophysi-
ology. In a case-referent study, which included magnetic 
resonance imaging brain imaging, stroke-free individuals 
with AF showed difficulties in learning, memory, attention 
and executive function compared with healthy referents 
[68]. Nonischemic mechanisms include cerebral hypoper-
fusion, vascular inflammation and genetic factors. Cerebral 
hypoperfusion and hypoxia have been demonstrated to be 
associated with increasing AF burden, and may be further 
worsened by concomitant heart failure with reduced ejection 
fraction [69–71]. There is growing evidence that implement-
ing use of DOACs and maintenance of sinus rhythm after 
cardioversion or catheter ablation, may reduce the risk of 
cognitive decline [72–75].
While the mechanisms of AF-related cognitive impair-
ment are multiple, interrelated and strongly associated to 
age-related changes [76–78], their consideration is essen-
tial in the management of older AF patients. As a conse-
quence, a cognitive screening should be part of the rou-
tine evaluation of AF patients, especially in advanced age. 
However, as in turn the diade cognitive impairment-AF in 
the context of the heart–brain syndrome is chacterized by a 
complex interaction of several interwoven factors—includ-
ing functional performance, psychosocial aspects, multi-
morbidity and polypharmacy-, a multidomain screening 
of the patient followed by a CGA in comanagement with 
the geriatrician appears to be the best available option to 
disentangle complexity and implement patient-centered, 
goal-oriented, value-based care in real life [79, 80]. Within 
a targeted CGA, a formal cognitive assessment would 
be helpful in AF patients, and cognitive impairment at 
mild-to moderate stage should not be viewed as a general 
contraindication to OAT, especially if well-managed from 
a logistically point of view. On the contrary, the appro-
priate management of AF has been consistently shown 
to improve cognitive performance [72, 73]. Similarly to 
cognitive impairment, predisposition to falls is common 
in frail patients, and is often perceived as an important 
issue in starting OAT. Patients on OAT at high risk of 
falls do not consistently have a significantly increased risk 
of major bleedings [34]. While a multidimensional frailty 
assessment with screening of cognitive and gait/motoric 
functions is helpful to disclose important components of 
clinical decision making, current guidelines do not require 
fall risk estimation in candidates to OAT. As in the pres-
ence of cognitive impairment, the risk of fall should not 
be considered per se as a contraindication to the use of 
DOACs of general AF management. On the contrary, gait 
disturbances arising from cerebral blood perfusion and 
orthostatic deregulation might considerably benefit from 
prompt diagnosis and management of AF.
Comorbidities and bleeding risk
Older patients with AF are at risk of stroke and throm-
boembolism; therefore, planning a proper anticoagulant 
treatment soon after the diagnosis is essential. Unfortu-
nately, advancing age is also associated with increased 
bleeding risk [81]. In this context, the bleeding risk (usu-
ally assessed through the HAS-BLED score) should not 
discourage physicians from prescribing OAT in patients 
with high risk of stroke, but rather prompt them to take 
action on controlling the modifiable bleeding risk factors 
and establishing a stricter and more frequent follow-up 
program [1]. Furthermore, these embolic and bleeding 
scores should be re-checked periodically in all AF patients 
[1].
Although previous bleeding events do not represent 
an absolute contraindication to OAT, there are several 
clinical situations which deserve a careful assessment 
in older AF patients. Older AF patients with spontane-
ous bleeding during OAT interruption, or unidentifiable 
or not treatable site of bleeding, or with recurrent bleed-
ing from multiple angiodysplasias in the gastrointestinal 
tract, should be carefully assessed about the opportunity 
of withholding OAT [82]. Although several observational 
cohort studies suggest a survival and thromboembolic 
benefit in those who restarted OAT after major bleeding 
(MB) events [83, 84], clinicians should also consider that 
AF patients aged 80 years or older with a previous major 
gastrointestinal bleeding experience the greatest mortal-
ity (roughly 45% and 65% at 2 and 5 years, respectively) 
[85]; therefore, shared decision-making on the basis of the 
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expected net clinical benefit is strongly advisable in these 
circumstances.
Physicians’ attitudes in prescribing OAT
Prescription of OAT to older AF patients is a more complex 
clinical decision than a simple calculation of cardio-embolic 
and bleeding risk scores. Clinicians are well aware that some 
or most of their older AF patients may have limited residual 
life-span because of a relevant burden of pathologies and/
or geriatric syndromes. Indeed, whereas in phase III DOAC 
trials all-cause mortality was 4.7%/year, with cardiac death 
contributing for 46% of deaths [86], real-world observational 
studies depict a different scenario. Among 186,461 Medicare 
beneficiaries (mean age 79.5 years) with AF, mortality was 
by far the most frequent major clinical events (occurring in 
19.5% at 1 year and 48.8% at 5 years) [85]. Although sev-
eral retrospective observational cohort studies demonstrated 
significant reduction of all-cause mortality in older patients 
treated with DOACs, regardless of poor health, functional 
conditions and multidimensional frailty, in most of these 
studies the mortality benefit was not accounted for by a sig-
nificant reduction of stroke, suggesting that at least in part 
this mortality benefit might represent a selection bias (that 
is, OAT is prescribed to those perceived with longer sur-
vival). In this context, implementation of standardized tools 
described above to evaluate short-term mortality in older 
AF patients might assist clinicians to address this therapy 
to those who may derive some benefit in their residual life-
span. The EUROSAF (European Study of Older Subjects 
with Atrial Fibrillation) project has begun to better accom-
pany the daily clinical choice of managing OAT in older 
people [87]. EUROSAF is an observational study aimed at 
assessing the effectiveness and risks of anticoagulant ther-
apy in frail older subjects with AF, stratified by the presence 
of frailty using the above described MPI [63, 87]. Some pre-
liminary data suggest that almost half of these patients are 
not treated with OAT, particularly if they are frail according 
to the MPI values [88]. Future data regarding the effect of 
anticoagulants (newer and older) could be important to see 
if frailty can be a significant determinant in mortality and 
cardiovascular events in people treated or not with OAT. In 
this context, the role of the CGA and its derivatives with 
high prognostic value such as the MPI, seems to be a crucial 
driver in taking clinical decisions in the frame of practical 
algorithms to be used in frail multi-morbid and poly-treated 
older patients with AF.
Unfortunately, uncertainties do not finish when com-
ing to the decision to prescribe OAT. The recent 2020 ESC 
guidelines recommend use of DOACs in preference to VKA, 
except for patients with prosthetic mechanical heart valves 
and moderate to severe mitral valve stenosis [1]. Several 
DOACs rankings [89–92] and expert opinions [93–96] have 
been published to assist physicians to select the DOAC 
Table 2  Dose adjustment of direct thrombin inhibitor and oral factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibril-
lation and specific conditions, according to the European Medicines Agency summary of product characteristics
OD once a day, BID two times a day, CrCl creatinine clearance, HIV human immunodeficiency virus
 ≠https:// www. ema. europa. eu/ en/ medic ines/ human/ EPAR/ xarel to
¶ https:// www. ema. europa. eu/ en/ medic ines/ human/ EPAR/ eliqu is
^https:// www. ema. europa. eu/ en/ medic ines/ human/ EPAR/ lixia na
Rivaroxaban≠ Apixaban¶ Edoxaban^ Dabigatran
Full dose 20 mg OD 5 mg BID 60 mg OD 150 mg BID
Age ≥ 80 years 20 mg OD 2.5 mg BID if another criterion* 60 mg OD 110 mg BID
Age 75–79 years 20 mg OD 5 mg BID 60 mg OD 110 mg BID for consideration
Body weight ≤ 60 kg 20 mg OD 2.5 mg BID if another criterion * 30 mg OD –
SerCr ≥ 1.5 mg/l – 2.5 mg BID if another criterion* – –
CrCl 30–49 ml/min 15 mg OD 5 mg BID 30 mg OD 110 mg BID for consideration
CrCl 15–29 ml/min 15 mg OD 2.5 mg BID 30 mg OD Not recommended
CrCl < 15 ml/min Not recommended Not recommended Not recommended Not recommended
Concomitant therapy:
Dronedarone Not recommended – 30 mg OD Not recommended
Cyclosporine – – 30 mg OD Not recommended
Erythromycin 20 mg OD – 30 mg OD –
Ketoconazole Not recommended Not recommended 30 mg OD Not recommended
HIV protease inhibitors 
(e.g., ritonavir)
Not recommended Not recommended – Not recommended
Verapamil – 5 mg BID 60 mg OD 110 mg BID
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according to individual patient’s characteristics. Apixaban 
has been demonstrated to have an excellent safety-efficacy 
balance, and suggested as a reasonable first choice either 
in older patients or in subjects with chronic renal failure 
[95]. The recently updated 2019 American Geriatrics Soci-
ety Beers criteria recommend a cautious use of dabigatran 
and rivaroxaban in AF patients aged ≥ 75 years because of 
greater risk of gastrointestinal bleeding [97]. In a recent 
report from the Fit-fOR-The-Aged (FORTA) classification 
(evaluating benefit, risk and appropriateness of drugs for 
older patients in everyday clinical settings), Apixaban was 
labelled A among OATs, meaning it was seen as the drug 
with the most favorable risk/benefit ratio in older patients 
[98].
These medications are fixed-dose oral regimens available 
in two different dose options, which have been variously 
named (standard, full or higher dose, and reduced or lower 
dose); anyway, dose prescription should be in keeping with 
drug-specific dosing guidelines (Table 2). However, as some 
clinicians get into difficulties in prescribing OAT to these 
complex older patients, many others also struggle with using 
DOAC recommended doses in this population. Indeed, sev-
eral studies from different settings and countries consistently 
reported high prevalence of inappropriate DOAC dosing, 
with inappropriate reduced dosing being largely prevalent, 
particularly in older patients [99–102].
In a recent review about the pros and cons of inappro-
priate underdosing of oral Factor Xa activated Inhibitors 
(oFXaIs) [103] we demonstrated that although some under-
dosing may be ascribed to involuntary errors, a substan-
tial proportion of it might reflect an intentional “cautious” 
approach to DOAC use in selected patients. Notably, very 
advanced age, female gender, presence of CKD, higher 
embolic and bleeding risk, previous bleeding or perceived 
high risk of bleeding, and concomitant use of antiplatelet 
drugs or nonsteroidal anti-inflammatory drugs (NSAIDs) 
were demonstrated to be associated with underdosing [103]. 
However, current evidence suggest that patients’ character-
istics rather than OAT intensity are associated with the risk 
of bleeding events, as suggested by the observation that the 
rates of MB in RCTs were higher among patients treated 
with oFXaIs at reduced dose than in those receiving full 
dose [104]. Moreover, real-life studies did not demonstrate a 
net clinical benefit by inappropriate underdosing of oFXaIs, 
but rather an increased risk of adverse events, including hos-
pitalizations for cardiovascular causes and stroke, without a 
significant reduction of bleeding events [103].
In this context, a potential novel therapeutic approach in 
older AF frail patients came from the recently published 
Edoxaban Low-Dose for Elder Care Atrial Fibrillation 
Patients (ELDERCARE-AF), which compared a once-
daily 15-mg dose of edoxaban with placebo in 984 Japa-
nese patients (mean age 86.6 years, 57.4% female) who had 
nonvalvular AF and in whom standard OAT was not recom-
mended for at least one of the following reasons: a low cre-
atinine clearance (15–30 ml per min), a history of bleeding 
from a critical area or organ or gastrointestinal bleeding, low 
body weight (≤ 45 kg), continuous use of NSAIDs, or cur-
rent use of an antiplatelet drug [92]. Among the 681 patients 
who completed the trial the annualized rate of stroke or sys-
temic embolism and MB were 2.3% vs 6.7% (p < 0.001), 
and 3.3% vs 1.8% (p = 0.09), in the edoxaban vs the placebo 
group, respectively, without substantial between-group dif-
ference in death from any cause [105]. These encouraging 
findings for a “humanitarian” OAT in the oldest patients 
should, however, be confirmed in other geographical areas 
and compared with appropriate DOAC doses before being 
considered an acceptable strategy in oldest patients.
Aspirin monotherapy was shown to be ineffective for 
stroke prevention in AF, as well as associated with increased 
risk of stroke in older patients [106]. Since the landmark 
BAFTA study [107], OAT (including warfarin and DOACs) 
has been consistently demonstrated to outweigh aspirin in 
terms of clinical net benefit in older AF patients [108–110]. 
The AVERROES study clearly demonstrated that is no evi-
dence of clinical benefit from prescribing antiplatelet ther-
apy compared with Apixaban to older AF patients [111], and 
current European recommendations strongly advice against 
this practice [1, 2], Likewise, use of dual antiplatelet therapy 
(DAPT) as an alternative to OAT is not recommended due 
to lower stroke prevention and similar bleeding rates [112].
Despite the increased bleeding risk, concomitant use of 
OAT and antiplatelets may become necessary due to inter-
ventions for coronary heart disease (CHD). Double anti-
platelet therapy (DAPT) for at least 12 months is a routine 
treatment approach after percutaneous coronary interven-
tions (PCI). However, in patients using OAT for AF, DAPT 
is recommended only for a short period (up to 1 month) for 
patients with acute CHD undergoing PCI. In this context, 
DOAC should be preferred, whenever possible, over war-
farin. Following a short period of triple therapy, treatment 
with DOAC and  P2Y12 inhibitor should be continued for 
12 months [1]. In selected patients, at very high thrombotic 
risk, triple therapy can sometimes be prolonged or single 
antiplatelet therapy continued along with DOAC for a longer 
period. This approach may seem appropriate due to the 
nature of thrombotic event or type of stent used. However, 
it may also become problematic and cause harm more than 
benefit, if the treatment approach is not based on a flex-
ible, individualized approach for older patients. It should be 
kept in mind that antiplatelet treatment should be no longer 
continued if a patient is already using an OAT and has a 
stable CHD (which refers to acute coronary syndrome or 
PCI more than 12 months ago) or peripheral artery disease 
(PAD) (PAD requiring an intervention more than 1 month 
ago) [113, 114].
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Inappropriate medication use and polypharmacy, 
drug–drug and drug–disease interactions are common and 
should be taken into account in older patients treated with 
OAT [115]. Especially, warfarin users should be closely 
monitored for several drug, supplement and food interac-
tions. NSAIDs should be avoided to reduce bleeding risk. 
Patients using concomitant OAT and antiplatelet therapy 
or corticosteroids should be given proton-pump inhibi-
tors to avoid gastrointestinal bleedings [116, 117]. Main 
drug–drug interactions of DOACs involve P-glycoprotein 
(P-gp) and CYP3A4 CYP2Y2 competition and inhibition. 
Major contraindications for increased anticoagulant effect 
include concomitant use of anti-fungal drugs (itraconazole, 
ketoconazole, voriconazole, posaconazole) and quinidine 
virtually for all DOACs. Clarythromicin and erythromycin 
increase the anticoagulant effect in DOAC-treated patients, 
as well as amiodarone and dronedarone do in patients receiv-
ing dabigatran, rivaroxaban and edoxaban: dose-adjustment 
or use of a different DOAC should be considered in these 
circumstances [34]. There is evidence that concurrent use of 
amiodarone, rifampin, fluconazole and phenytoin in patients 
taking DOACs is associated with increased risk of MB com-
pared with use of DOACs alone [118]. Furthermore, supple-
ments commonly used in older adults (like ginkgo biloba) 
can cause serious bleedings when used concomitantly with 
OAT [114]. There is increasing evidence of several other 
drug interactions with potential clinical significance, includ-
ing antineoplastic and antiepileptic drugs, of common use in 
older patients [2]. Therefore, use of DOACs in older patients 
mandate a careful evaluation of co-medications to optimize 
therapy and select the most appropriate drug and dose [34, 
114].
Conclusions and outlook
As the world population grows in terms of size and age, 
the challenges related to diagnosis and management of AF 
are also expected to rise and pose healthcare practitioners 
the multifaceted challenges of complexity [119]. These 
include—far beyond organ-related medicine, multimorbid-
ity and/or chronological age—aspects related to age-related 
physiological changes, physical and cognitive functional 
impairment as well as multidimensional frailty—a surrogate 
marker of biological age.
While geriatric medicine provides a series of screening 
methods targeting AF-influencing domains such as daily 
functions, social status, cognitive performance, mood and 
nutrition, evidence on the systematic comanaged adop-
tion and interpretation of the CGA in older AF patients is 
lacking. This would be the necessary next step to improve 
recommendations and guidelines in the near future and the 
basis for implementation of CGA in clinical routine. CGA-
based instruments, indeed, help to optimizing the patient-
centered decisions in older AF patients. To inform this 
evidence and improve recommendations and guidelines 
in the near future, further systematic research is necessary 
to link results of the CGA to patient outcomes, treatment 
benefits/risk and clinical decision making.
Expert opinion box
• The large majority of AF patients are old-old and old-
est-old. Recent DOACs RCTs, which demonstrated net 
clinical benefit over warfarin, mostly excluded oldest-
old, frail and cognitively impaired individuals.
• Although RCTs and observational studies demonstrated 
that DOACs provide clinical benefit over warfarin in 
the majority of older patients, there is scant evidence 
of net clinical benefit in frail, disabled and severely 
cognitive impaired patients
• Due to the lack of evidence, physicians' attitudes pre-
vail, with high risk of undertreatment and, at the same 
time, of futile therapy. Decisions regarding AF treat-
ment in older adults require a more specific and holistic 
approach; CGA, MPI and appropriate frailty tools may 
assist physicians in clinical decision making
• The risk of fall should not be considered a contraindi-
cation to the use of DOACs. High bleeding risk should 
not be interpreted as a contraindication to the use of 
OAT, but should direct physicians to assess and manage 
modifiable bleeding risk factors.
• Inappropriate DOAC dosing, especially inappropriate 
“reduced” dosing is highly prevalent in older adults, 
but real-life studies do not provide evidence of a net 
clinical benefit of this strategy. Use of antiplatelet ther-
apy as an alternative to OAT is not recommended, due 
to lower stroke prevention and high bleeding rates.
• Opportunistic screening of AF in older population is 
cost-effective and should be performed by pulse palpa-
tion or ECG rhythm strip. Annual events (like influenza 
vaccination) can be a good opportunity for AF screen-
ing in older adults.
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